Continuum of Care in the Treatment of ST-Segment Elevation Myocardial Infarction (STEMI): Importance of Platelet and Coagulation Inhibition

References

• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115(5): e69–e171.
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American. College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004; 110(5): 588–636.
   PubMed Web of Science ®Google Scholar
• Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AH A 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008; 117(2): 296–329.
   PubMed Web of Science ®Google Scholar
• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104(3): 365–372.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9): 1135–1143.
   PubMed Web of Science ®Google Scholar
• Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol. 2004; 4(2): 166–170.
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med. 1998; 3(3): 231–239.
   PubMedGoogle Scholar
• Cattaneo M. Aspirin and Clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vase Biol. 2004; 24(11): 1980–1987.
   PubMed Web of Science ®Google Scholar
• Huang F, Hong E. Platelet glycoprotein IIb/IIIa inhibition and its clinical use. Curr Med Chem Cardiovasc Hematol Agents. 2004; 2(3): 187–196.
   PubMedGoogle Scholar
• Majerus PW, Broze GJ, Miletich JP, et al. Anticoagulant, Thrombolytic, and Antiplatelet Drugs. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996: 1341–1359.
   Google Scholar
• The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J. 1996; 17(1): 43–63.
   Web of Science ®Google Scholar
• Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez- Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002; 359(9304): 373–377.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bahit MC, Haugland JM. Underutilization of evidence- based medications in acute ST elevations myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002; 1(1): 44–52.
   PubMedGoogle Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336(8707): 65–71.
   PubMed Web of Science ®Google Scholar
• ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992; 339(8796): 753–770.
   PubMed Web of Science ®Google Scholar
• Sinnaeve PR, Alexander JH, Bogaerts K, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J. 2004; 147(6): 993–998.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003; 108(2): 135–142.
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354(14): 1477–1488.
   PubMed Web of Science ®Google Scholar
• Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007; 49(23): 2249–2255.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295(13): 1519–1530.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357(9272): 1905–1914.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Califf RM, Van de Werf F; Global Use of Strategies to Open Coronary Arteries Investigators (GUSTO). Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002; 288(17): 2130–2135.
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358(9282): 605–613.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006; 367(9510): 579–588.
   PubMed Web of Science ®Google Scholar
• Sinno MC, Khanal S, Al-Mallah MH, Arida M, Weaver WD. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Am Heart J. 2007; 153(4): 579–586.
   PubMed Web of Science ®Google Scholar
• Kindermann M, Adam O, Werner N, Bohm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol. 2007; 96(11): 767–786.
   PubMed Web of Science ®Google Scholar
• Recio-Mayoral A, Kaski JC, McMurray JJ, Horowitz J, van Veldhuisen DJ, Remme WJ. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther. 2007; 21(6): 459–465.
   PubMed Web of Science ®Google Scholar
• Legutko J, Rakowski T, Siudak Z, et al. Efficacy and safety of early Clopidogrel administration with or without abciximab in patients with ST-segment elevation myocardial infarction transferred for primary PCI. Results from the EUROTRANSFER Registry. J Am Coll Cardiol. 2008; (51 Suppl); A212.
   Google Scholar
• Kastrati K. TRANSFER-MI. http://www.heart.org/downloadable/heart/1206910545859Transfer_AMI.pps#28 Accessed June 06, 2008.
   Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation. N Engl J Med. 2005; 352(12): 1179–1189.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of Clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294(10): 1224–1232.
   Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of Clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366(9497): 1607–1621.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345(7): 494–502.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fiather MD, Hacke W, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49(19): 1982–1988.
   PubMed Web of Science ®Google Scholar
• Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001; 357(9262): 1063–1068.
   PubMed Web of Science ®Google Scholar
• Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001; 285(4): 430–436.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15): 1495–1504.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–2572.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10): 669–677.
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342(8875): 821–828.
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995; 92(10): 3132–3137.
   PubMed Web of Science ®Google Scholar
• The Beta-Blocker Pooling Project Research Group. The Beta-'Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988; 9(1): 8–16.
   Web of Science ®Google Scholar
• Barron HV, Viskin S, Lundstrom RJ, et al. Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: data from a large HMO. Am Heart J. 1997; 134(4): 608–613.
   PubMed Web of Science ®Google Scholar
• Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med., 2000; 160(7): 947–952.
   PubMedGoogle Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71–86.
   PubMed Web of Science ®Google Scholar
• CRUSADE. Seeking to improve the evidenced-based care of NSTE ACS patients nationwide. January 2007. http://www.crusadeqi.com/Main/AboutUs.shtml. Accessed May 21, 2008.
   Google Scholar
• Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006; 295(16): 1912–1920.
   PubMed Web of Science ®Google Scholar
• Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002; 287(10): 1269–1276.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001; 87(7): 819–822.
   PubMed Web of Science ®Google Scholar
• LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004; 164(2): 203–209.
   PubMedGoogle Scholar
• Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J. 2004; 148(5 Suppl): S29–S33.
   Web of Science ®Google Scholar